CNS Drugs

, Volume 16, Issue 9, pp 595–609 | Cite as

Clinical Implications of CNS Penetration of Antiretroviral Drugs

  • Heather E. Wynn
  • Richard C. Brundage
  • Courtney V. Fletcher
Review Article

Abstract

The CNS serves as an important sanctuary site for HIV replication. The presence of HIV in this compartment may contribute to neurological complications in individuals infected with HIV. Understanding the CNS penetration capabilities of available antiretroviral agents may help clinicians to design treatment regimens with neuroprotective effects. Although numerous clinical studies and anecdotal reports have examined CSF antiretroviral drug exposure as a marker of CNS penetration, understanding the clinical relevance of these findings is difficult. Challenges with study design and subject recruitment often limit the investigator’s ability to collect comprehensive data. Upon review of available data, the antiretroviral agents zidovudine, stavudine, lamivudine, nevirapine, efavirenz and indinavir demonstrate consistent penetration into the CSF. Zidovudine-, stavudine-, lamivudine-, didanosine- and protease inhibitor-based regimens also appear to suppress CSF viraemia or improve HIV neurological disease. These agents may be appropriate candidates for neuroprotective antiretroviral treatment regimens. Despite these data, several unanswered questions about the CSF antiretroviral drug exposure-response relationship still remain. Prospective, controlled studies examining this relationship are needed before absolute clinical recommendations are founded.

Keywords

Zidovudine Ritonavir Efavirenz Nevirapine Indinavir 

Notes

Acknowledgements

The authors received grant support (R01 AI33835 and UO1 AI41089) from the National Institutes of Health.

References

  1. 1.
    Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853–60PubMedCrossRefGoogle Scholar
  2. 2.
    Hoetelmans RM. Sanctuary sites in HIV-1 infection. Antivir Ther 1998; 3: 13–7PubMedGoogle Scholar
  3. 3.
    Brew BJ, Pemberton L, Cunningham P, et al. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis 1997; 175: 963–6PubMedCrossRefGoogle Scholar
  4. 4.
    Cinque P, Vago L, Ceresa D, et al. Cerebrospinal fluid HIV-1 RNA levels: correlation with HIV encephalitis. AIDS 1998; 12: 389–94PubMedCrossRefGoogle Scholar
  5. 5.
    Ellis RJ, Hsia K, Spector SA, et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome: HIV Neurobehavioral Research Center Group. Ann Neurol 1997; 42: 679–88PubMedCrossRefGoogle Scholar
  6. 6.
    McArthur JC, McClernon DR, Cronin MF, et al. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 1997; 42: 689–98PubMedCrossRefGoogle Scholar
  7. 7.
    Mastroianni CM, Trinchieri V, Santopadre P, et al. Reversal of AIDS dementia after combination therapy with stavudine, lamivudine, and nelfinavir. J Neurol 1999; 246: 972–3PubMedCrossRefGoogle Scholar
  8. 8.
    Rosenfeldt V, Valerius NH, Paerregaard A. Regression of HIV-associated progressive encephalopathy of childhood during HAART. Scand J Infect Dis 2000; 32: 571–4PubMedCrossRefGoogle Scholar
  9. 9.
    Acosta EP, Henry K, Baken L, et al. Indinavir concentrations and antiviral effect. Pharmacotherapy 1999; 19: 708–12PubMedCrossRefGoogle Scholar
  10. 10.
    Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21–30PubMedGoogle Scholar
  11. 11.
    Henry KW, Worley J, Sullivan C, et al. Documented improvement in late stage manifestations of AIDS after starting ritonavir in combination with two reverse transcriptase inhibitors [abstract no. 356]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington, DC. Alexandria (VA): Foundation for Retrovirology and Human Health, 1997: 130Google Scholar
  12. 12.
    Stellbrink HJ, Eggers C, van Lunzen J, et al. Rapid decay of HIV RNA in the cerebrospinal fluid during antiretroviral combination therapy. AIDS 1997; 11: 1655–7PubMedCrossRefGoogle Scholar
  13. 13.
    Gisslen M, Hagberg L, Svennerholm B, et al. HIV-1 RNA is not detectable in the cerebrospinal fluid during antiretroviral combination therapy [letter]. AIDS 1997; 11: 1194PubMedCrossRefGoogle Scholar
  14. 14.
    Gisslen M, Norkrans G, Svennerholm B, et al. HIV-1 RNA detectable with ultrasensitive quantitative polymerase chain reaction in plasma but not in cerebrospinal fluid during combination treatment with zidovudine, lamivudine and indinavir. AIDS 1998; 12: 114–6PubMedGoogle Scholar
  15. 15.
    Kravcik S, Gallicano K, Roth V, et al. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir. J Acquir Immune Defic Syndr 1999; 21: 371–5PubMedGoogle Scholar
  16. 16.
    Gisolf EH, Enting RH, Jurriaans S, et al. Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine. AIDS 2000; 14: 1583–9PubMedCrossRefGoogle Scholar
  17. 17.
    Goldstein GW, Betz AL. The blood-brain barrier. Sci Am 1986; 255: 74–83PubMedCrossRefGoogle Scholar
  18. 18.
    Spector R, Johanson CE. The mammalian choroid plexus. Sci Am 1989; 261: 68–74PubMedCrossRefGoogle Scholar
  19. 19.
    Rosenburg GA, editor. Anatomy of brain interfaces. Brain fluids and metabolism. New York: Oxford Press, 1990Google Scholar
  20. 20.
    Ghersi-Egea JF, Strazielle N. Brain drug delivery, drug metabolism and multi-drug resistance at the choroid plexus. Microsc Res Tech 2001; 52: 83–8PubMedCrossRefGoogle Scholar
  21. 21.
    Rosenburg GA, editor. Physiology of cerebrospinal and interstitial fluids. Brain fluids and metabolism. New York: Oxford Press, 1990Google Scholar
  22. 22.
    Begley DJ, Khan EU, Rollinson C, et al. The role of brain extracellular fluid production and efflux mechanism in drug transport to the brain. In: Begley DJ, Bradbury MW, Kreuter J, editors. The blood-brain barrier and drug delivery to the CNS. New York: Marcel Dekker, Inc., 2000Google Scholar
  23. 23.
    Takasawa K, Terasaki T, Suzuki H, et al. In vivo evidence for carrier-mediated efflux transport of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system. J Pharmacol Exp Ther 1997; 281: 369–75PubMedGoogle Scholar
  24. 24.
    Burger DM, Meenhorst PL, Beijnen JH. Concise overview of the clinical pharmacokinetics of dideoxynucleoside antiretroviral agents. Pharm World Sci 1995; 17: 25–30PubMedCrossRefGoogle Scholar
  25. 25.
    Sommadossi JP. HIV protease inhibitors: pharmacologic and metabolic distinctions. AIDS 1999; 13Suppl. 1: S29–40PubMedGoogle Scholar
  26. 26.
    Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101: 289–94PubMedCrossRefGoogle Scholar
  27. 27.
    Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000; 14: 237–42PubMedCrossRefGoogle Scholar
  28. 28.
    Rolinski B, Bogner JR, Sadri I, et al. Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15: 192–7PubMedCrossRefGoogle Scholar
  29. 29.
    Haas DW, Clough LA, Johnson BW, et al. Evidence of a source of HIV type 1 within the central nervous system by ultra-intensive sampling of cerebrospinal fluid and plasma. AIDS Res Hum Retroviruses 2000; 16: 1491–502PubMedCrossRefGoogle Scholar
  30. 30.
    Haas DW, Stone J, Clough LA, et al. Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection. Clin Pharmacol Ther 2000; 68: 367–74PubMedCrossRefGoogle Scholar
  31. 31.
    Anderson PL, Brundage RC, Bushman L, et al. Indinavir plasma protein binding in HIV-1-infected adults. AIDS 2000; 14: 2293–7PubMedCrossRefGoogle Scholar
  32. 32.
    Yost RL, DeVane CL. Diurnal variation of alpha 1-acid glycoprotein concentration in normal volunteers. J Pharm Sci 1985; 74: 777–9PubMedCrossRefGoogle Scholar
  33. 33.
    Sadler BM, Gillotin C, Lou Y, et al. In vivo effect of alpha(1)-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 2001; 45: 852–6PubMedCrossRefGoogle Scholar
  34. 34.
    Tartaglione TA, Collier AC, Coombs RW, et al. Acquired immunodeficiency syndrome: cerebrospinal fluid findings in patients before and during long-term oral zidovudine therapy. Arch Neurol 1991; 48: 695–9PubMedCrossRefGoogle Scholar
  35. 35.
    Burger DM, Kraaijeveld CL, Meenhorst PL, et al. Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV. AIDS 1993; 7: 1581–7PubMedCrossRefGoogle Scholar
  36. 36.
    Elovaara I, Poutiainen E, Lahdevirta J, et al. Zidovudine reduces intrathecal immunoactivation in patients with early human immunodeficiency virus type 1 infection. Arch Neurol 1994; 51: 943–50PubMedCrossRefGoogle Scholar
  37. 37.
    Klecker Jr RW, Collins JM, Yarchoan R, et al. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythy-midine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther 1987; 41: 407–12PubMedCrossRefGoogle Scholar
  38. 38.
    Lane HC, Falloon J, Walker RE, et al. Zidovudine in patients with human immunodeficiency virus (HIV) infection and Kaposi sarcoma: a phase II randomized, placebo-controlled trial. Ann Intern Med 1989; 111: 41–50PubMedGoogle Scholar
  39. 39.
    Yarchoan R, Thomas RV, Grafman J, et al. Long-term administration of 3′-azido-2′,3′-dideoxythymidine to patients with AIDS-related neurological disease. Ann Neurol 1988; 23 Suppl.: S82–7PubMedCrossRefGoogle Scholar
  40. 40.
    Yarchoan R, Berg G, Brouwers P, et al. Response of human-immunodeficiency-virus-associated neurological disease to 3′-azido-3′-deoxythymidine. Lancet 1987; I: 132–5CrossRefGoogle Scholar
  41. 41.
    Surbone A, Yarchoan R, McAtee N, et al. Treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex with a regimen of 3′-azido-2′,3′-dideoxythymidine (azidothymidine or zidovudine) and acyclovir: a pilot study. Ann Intern Med 1988; 108: 534–40PubMedGoogle Scholar
  42. 42.
    Pizzo PA, Eddy J, Falloon J, et al. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med 1988; 319: 889–96PubMedCrossRefGoogle Scholar
  43. 43.
    Balis FM, Pizzo PA, Murphy RF, et al. The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann Intern Med 1989; 110: 279–85PubMedGoogle Scholar
  44. 44.
    KleckerJr RW, Collins JM, Yarchoan RC, et al. Pharmacokinetics of 2′,3′-dideoxycytidine in patients with AIDS and related disorders. J Clin Pharmacol 1988; 28: 837–42PubMedGoogle Scholar
  45. 45.
    Yarchoan R, Mitsuya H, Thomas RV, et al. In vivo activity against HIV and favorable toxicity profile of 2′,3′-dideoxyinosine. Science 1989; 245: 412–5PubMedCrossRefGoogle Scholar
  46. 46.
    Hartman NR, Yarchoan R, Pluda JM, et al. Pharmacokinetics of 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther 1990; 47: 647–54PubMedCrossRefGoogle Scholar
  47. 47.
    Balis FM, Pizzo PA, Butler KM, et al. Clinical pharmacology of 2′,3′-dideoxyinosine in human immunodeficiency virus-infected children. J Infect Dis 1992; 165: 99–104PubMedCrossRefGoogle Scholar
  48. 48.
    Burger DM, Kraayeveld CL, Meenhorst PL, et al. Study on didanosine concentrations in cerebrospinal fluid: implications for the treatment and prevention of AIDS dementia complex. Pharm World Sci 1995; 17: 218–21PubMedCrossRefGoogle Scholar
  49. 49.
    Dudley MN, Graham KK, Kaul S, et al. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J Infect Dis 1992; 166: 480–5PubMedCrossRefGoogle Scholar
  50. 50.
    Kline MW, Dunkle LM, Church JA, et al. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics 1995; 96: 247–52PubMedGoogle Scholar
  51. 51.
    Haworth SJ, Christofalo B, Anderson RD, et al. A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17: 235–8PubMedCrossRefGoogle Scholar
  52. 52.
    vanLeeuwen R, Katlama C, Kitchen V, et al. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J Infect Dis 1995; 171: 1166–71PubMedCrossRefGoogle Scholar
  53. 53.
    Lewis LL, Venzon D, Church J, et al. Lamivudine in children with human immunodeficiency virus infection: a phase I/II study: The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. J Infect Dis 1996; 174: 16–25PubMedCrossRefGoogle Scholar
  54. 54.
    Mueller BU, Lewis LL, Yuen GJ, et al. Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children. Anti-microb Agents Chemother 1998; 42: 3187–92Google Scholar
  55. 55.
    Blaschke AJ, Capparelli EV, Ellis RJ, et al. A population model-based approach for determining lamivudine (3TC) cerebrospinal fluid (CSF) penetration in HIV-infected adults [abstract no. 310]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco. Alexandria (VA): Foundation for Retrovirology and Human Health, 2000: 135Google Scholar
  56. 56.
    Foudraine NA, Hoetelmans RM, Lange JM, et al. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 1998; 351: 1547–51PubMedCrossRefGoogle Scholar
  57. 57.
    McDowell JA, Chittick GE, Ravitch JR, et al. Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob Agents Chemother 1999; 43: 2855–61PubMedGoogle Scholar
  58. 58.
    McDowell JA, Lou Y, Symonds WS, et al. Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2000; 44: 2061–7PubMedCrossRefGoogle Scholar
  59. 59.
    Gisslen M, Norkrans G, Svennerholm B, et al. The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine. J Infect Dis 1997; 175: 434–7PubMedCrossRefGoogle Scholar
  60. 60.
    Englund JA, Baker CJ, Raskino C, et al. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children: AIDS Clinical Trials Group (ACTG) Study 152 Team. N Engl J Med 1997; 336: 1704–12PubMedCrossRefGoogle Scholar
  61. 61.
    Smith PF, DiCenzo R, Morse GD. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 2001; 40: 893–905PubMedCrossRefGoogle Scholar
  62. 62.
    Prins J, van Praag R, Jurrians S, et al. Drug levels and HIV-1 RNA in serum and CSF during treatment with a five-drug regimen: AZT, 3TC, abacavir, nevirapine (NVP), and indinavir [abstract no. 309]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco. Alexandria (VA): Foundation for Retrovirology and Human Health, 2000: 135Google Scholar
  63. 63.
    Kearney B, Price R, Sheiner L, et al. Estimation of nevirapine exposure within the cerebrospinal fluid using CSF: plasma area under the curve ratios [abstract no. 406]. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago. Alexandria (VA): Foundation for Retrovirology and Human Health, 1999: 144Google Scholar
  64. 64.
    Tashima KT, Caliendo AM, Ahmad M, et al. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. J Infect Dis 1999; 180: 862–4PubMedCrossRefGoogle Scholar
  65. 65.
    Fletcher CV, Brundage RC, Remmel RP, et al. Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy. Antimicrob Agents Chemother 2000; 44: 1029–34PubMedCrossRefGoogle Scholar
  66. 66.
    Stahle L, Martin C, Svensson JO, et al. Indinavir in cerebrospinal fluid of HIV-1-infected patients [letter]. Lancet 1997; 350: 1823PubMedCrossRefGoogle Scholar
  67. 67.
    Collier AC, Marra C, Coombs RW, et al. Cerebrospinal fluid (CSF) indinavir (IDV) and HIV RNA levels in patients on chronic indinavir therapy [abstract no. 22]. 35th Annual Meeting of the Infectious Diseases Society of America; 1997 Sep 13–16; San Francisco, 75Google Scholar
  68. 68.
    Martin C, Sonnerborg A, Svensson JO, et al. Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system. AIDS 1999; 13: 1227–32PubMedCrossRefGoogle Scholar
  69. 69.
    Zhou XJ, Havlir DV, Richman DD, et al. Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. AIDS 2000; 14: 2869–76PubMedCrossRefGoogle Scholar
  70. 70.
    Brinkman K, Kroon F, Hugen PW, et al. Therapeutic concentrations of indinavir in cerebrospinal fluid of HIV-1-infected patients [letter]. AIDS 1998; 12: 537PubMedCrossRefGoogle Scholar
  71. 71.
    Gendelman HE, Zheng J, Coulter CL, et al. Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia. J Infect Dis 1998; 178: 1000–7PubMedCrossRefGoogle Scholar
  72. 72.
    van Praag RM, Weverling GJ, Portegies P, et al. Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS 2000; 14: 1187–94PubMedCrossRefGoogle Scholar
  73. 73.
    Letendre SL, Caparelli E, Ellis RJ, et al. Levels of serum and cerebrospinal fluid (CSF) indinavir (IDV) and HIV-infected individuals [abstract no. 407]. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago. Alexandria (VA): Foundation for Retrovirology and Human Health, 1999: 144Google Scholar
  74. 74.
    Polis M, Yoder C, Mican J, et al. More than 2 months of an aggressive 4-drug antiretroviral regimen is required to suppress CSF HIV viral burden in previously antiretroviral naive patients [abstract no. 404]. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago. Alexandria (VA): Foundation for Retrovirology and Human Health, 1999: 143Google Scholar
  75. 75.
    Aweeka F, Jayewardene A, Staprans S, et al. Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS dementia complex. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 39–43PubMedCrossRefGoogle Scholar
  76. 76.
    Murphy R, Currier J, Gerber J, et al. Antiviral activity and pharmacokinetics of amprenavir with or without zidovudine/ 3TC in the cerebral spinal fluid of HIV-infected adults [abstract no. 314]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco. Alexandria (VA): Foundation for Retrovirology and Human Health, 2000: 135Google Scholar
  77. 77.
    Moyle GJ, Sadler M, Buss N. Plasma and cerebrospinal fluid saquinavir concentrations in patients receiving combination antiretroviral therapy. Clin Infect Dis 1999; 28: 403–4PubMedCrossRefGoogle Scholar
  78. 78.
    Cameron DW, Japour AJ, Xu Y, et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 1999; 13: 213–24PubMedCrossRefGoogle Scholar
  79. 79.
    Sacktor NC, Lyles RH, Skolasky RL, et al. Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men: Multicenter AIDS Cohort Study (MACS). Neurology 1999; 52: 1640–7PubMedCrossRefGoogle Scholar
  80. 80.
    Sacktor NC, Skolasky RL, Lyles RH, et al. Improvement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors. J Neurovirol 2000; 6: 84–8PubMedCrossRefGoogle Scholar
  81. 81.
    Filippi CG, Sze G, Farber SJ, et al. Regression of HIV encephalopathy and basal ganglia signal intensity abnormality at MR imaging in patients with AIDS after the initiation of protease inhibitor therapy. Radiology 1998; 206: 491–8PubMedGoogle Scholar
  82. 82.
    Tepper VJ, Farley JJ, Rothman MI, et al. Neurodevelopmental/ neuroradiologic recovery of a child infected with HIV after treatment with combination antiretroviral therapy using the HIV-specific protease inhibitor ritonavir [letter]. Pediatrics 1998; 101: E7PubMedCrossRefGoogle Scholar
  83. 83.
    Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996; 2: 760–6PubMedCrossRefGoogle Scholar
  84. 84.
    Garcia F, Niebla G, Romeu J, et al. Cerebrospinal fluid HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV-1 infection: support for the hypothesis of local virus replication. AIDS 1999; 13: 1491–6PubMedCrossRefGoogle Scholar
  85. 85.
    Cunningham PH, Smith DG, Satchell C, et al. Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid. AIDS 2000; 14: 1949–54PubMedCrossRefGoogle Scholar
  86. 86.
    Venturi GCM, Romano L, Corsi P, et al. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples. J Infect Dis 2000; 181: 740–5PubMedCrossRefGoogle Scholar
  87. 87.
    Anderson BD, Morgan ME, Singhal D. Enhanced oral bioavailability of DDI after administration of 6-Cl-ddP, an adenosine deaminase-activated prodrug, to chronically catheterized rats. Pharm Res 1995; 12: 1126–33PubMedCrossRefGoogle Scholar
  88. 88.
    Sawchuk RJ, Hedaya MA. Modeling the enhanced uptake of zidovudine (AZT) into cerebrospinal fluid. 1: effect of probenecid. Pharm Res 1990; 7: 332–8PubMedCrossRefGoogle Scholar
  89. 89.
    Mayer U, Wagenaar E, Dorobek B, et al. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 1997; 100: 2430–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • Heather E. Wynn
    • 1
  • Richard C. Brundage
    • 1
  • Courtney V. Fletcher
    • 2
  1. 1.Department of Experimental and Clinical PharmacologyUniversity of Minnesota College of PharmacyMinneapolisUSA
  2. 2.Antiviral Pharmacology LaboratoryUniversity of Colorado Health Sciences CenterDenverUSA

Personalised recommendations